Armata PharmaceuticalsvsJohnson & Johnson

ARMP and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ARMP

Armata Pharmaceuticals, Inc.

$3.03

Value $111M

+1.68%
ARMP's page

Armata Pharmaceuticals (ARMP) has a market value of $111M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, ARMP moved -58.5% and JNJ +36.6%. Dividend yield: ARMP none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARMP$111M

    JNJ$652B

    JNJ is 5,872 times ARMP

  • Revenue, 12 months

    ARMP–

    JNJ$99.3B

  • Net income, 12 months

    ARMP-$111M

    JNJ$16.1B

  • Operating margin

    ARMP–

    JNJ–

  • ROIC

    ARMP–

    JNJ12.4%

  • P/E

    ARMP–

    JNJ40.5

  • Dividend yield

    ARMP0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    ARMP-22.7%

    JNJ+90.9%

    113.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARMP-22.8%

JNJ+90.9%

10020030020222023202420252026
Returns by period
PeriodARMPWith dividendsJNJWith dividends
1 year since November 19, 2025-58.5%Price -58.5%+36.6%Price +33.6%
3 years since November 20, 2023+37.7%+11.3% a yearPrice +37.7%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-22.7%-5.0% a yearPrice -22.7%+90.9%+13.8% a yearPrice +66.0%
10 years since November 22, 2016-96.5%-28.5% a yearPrice -96.5%+212.6%+12.1% a yearPrice +139.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARMPArmata PharmaceuticalsJNJJohnson & Johnson

Valuation

ARMPJNJ
Valuation
Price$3.03$270.47
Market value$111M$652B
Enterprise value (EV)$341M$679B
P/E–40.5
P/E, 5-year median–21.9
P/B–8.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

ARMPJNJ
Results and growth
Revenue, 12 months–$99.3B
Net income, 12 months-$111M$16.1B
Free cash flow, 12 months-$27M$20.6B
Earnings per share, 12 months-$7.10$6.59
Revenue growth, year on year–6.1%
Revenue growth a year, past–+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ARMPJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin––
Net margin–16.2%
ROIC–12.4%
ROE–19.7%

Balance sheet

ARMPJNJ
Balance sheet
Cash$18M$17.2B
Total debt$278M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

ARMPJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARMP or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Armata Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 5,872.3 times Armata Pharmaceuticals ($111M), at today's prices.

How did ARMP and JNJ stock do over the last 10 years?

Since November 22, 2016, ARMP's price moved -96.5% and JNJ's +139.9%. With dividends: ARMP -96.5% (-28.5% a year), JNJ +212.6% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARMP or JNJ?

The dividend yield at today's price is none for Armata Pharmaceuticals and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which is the better investment, Armata Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.